TITLE:
Soft Tissue Sarcomas: Descriptive Study of 232 Cases Collected, over a Period of 10 Years, at the Hospital of Oncology, Department of the Hassan II Hospital FEZ
AUTHORS:
Oumaima Siyouri, Hajar Medyouni, Jihane Chouef, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Samia Arifi, Nawfel Mellas
KEYWORDS:
Soft Tissue Sarcomas, STS, Chemotherapy, Leiomyosarcoma
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.14 No.3,
March
21,
2023
ABSTRACT: Soft-tissue sarcomas are uncommon tumors that have traditionally been
managed by wide excisional surgery and radiotherapy; the use of chemotherapy has been reserved for advanced disease. Advances
in multidisciplinary care have improved the evaluation and care of patients
with this disease. Limb-conserving
surgical paradigms, superior radiotherapy delivery, and novel adjuvant
agents for specific tumors are now available. The objective of this study is to
report the epidemiological, clinical, histological, therapeutic and
evolutionary characteristics of soft tissue sarcomas at the oncology hospital: Chu
Hassan II in FEZ, and to define the factors influencing patient survival. This
is a retrospective study of 232 cases of soft tissue sarcoma, collected between
January 2010 and June 2020. The eligibility criteria were an age greater than
16 years, and histological evidence of a soft tissue sarcoma excluding gastrointestinal
stromal tumors (GIST). Items collected were: epidemiological, clinical,
histological, radiological, and therapeutic. These are 232 cases, 120 Men and
112 Women, the mean age was 48.89 years (Extreme = 18 - 76
years). The tumor was localized to the extremities at (58.72%). The predominant histological type was Leiomyosarcoma in 61 cases
(26.29%). The tumor stage was localized in (17.67%) of cases, locally advanced
in 34.05% and metastatic in 44.08% of patients, all localized cases were
treated surgically including (84%) conservative surgery and (16%) radical
surgery. Radiation therapy was performed in 32.75% of patients. Chemotherapy
was performed in 74.14% of patients. Age and tumor stage are prognostic factors
influencing the survival of soft tissue sarcomas.